Higher levels of cancer-related financial toxicity are associated with decreased quality of life, poorer treatment adherence, and poorer survival for adult patients with cancer.
There’s a national health and economic crisis hiding in plain sight that causes patients and families fighting cancer to be unable to adhere to their treatment plans and instead drives them to financial ruin and shortens their lives: cancer-related financial toxicity (CRFT). The pervasive effects of CRFT as a result of disease-related income loss and increased out-of-pocket (OOP) costs associated with cancer treatment are explored in a new white paper, “Cancer-Related Financial Toxicity and its Pervasive Effects on Patients and Families: Solving a National Health and Economic Crisis Hiding in Plain Sight,” produced by Family Reach, a national nonprofit organization dedicated to alleviating the financial burden of cancer, with the support of Xcenda.
Direct medical expenditures for cancer are projected to total at least $158 billion by 2020, and patients and their families pay about $4 billion per year in OOP costs associated with cancer treatment. The substantial financial effect on families can be catastrophic; CRFT is a debilitating side-effect of cancer treatment, the white paper suggests, and occurs when the OOP costs of treatment are high relative to a family’s already diminished income, as treatment often requires patients and families to reduce work hours significantly. Part of the fallout from CRFT, in addition to the social and clinical consequences of cancer, such as reduced quality of life and increased psychosocial hardship, are poorer treatment adherence and decreased survival.
CRFT is widespread among patients with cancer and their families. Up to 73% of adult patients with cancer experience some sort of CRFT, which causes a chain-reaction of ill effects:
It is not just uninsured patients who face catastrophic financial burdens. Even insured patients are vulnerable to CRFT because many have insurance plans with high levels of cost-sharing. Many patients, especially lower-income patients, are attracted to insurance plans with lower monthly premiums, but learn later that they have to pay high OOP costs for cancer care. Compounding the situation, OOP costs for cancer recurrence can be up to 3 times greater than OOP costs experienced for the initial treatment.
The need for interventions to alleviate CRFT is increasing, in part because of a steady rise in cost-sharing health insurance plans. Premiums for family coverage have increased 20% since 2011 and 58% since 2006. Other forms of cost-sharing, such as deductibles, copayments, and coinsurance, have also increased.
Family Reach concludes that a multicomponent approach to financial interventions will help to address CRFT. “Financial navigation, financial planning, education, and financial assistance provided to patients early and throughout their cancer journey will likely have the greatest impact on reducing financial barriers to treatment adherence and improving disease outcomes.”
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.